Johnson & Johnson’s antibody-based therapy candidate nipocalimab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe Sjögren’s disease. This status is meant to accelerate the development and regulatory review of investigational therapies intended to treat serious…